2006 proposed fee schedule - American Society of Clinical Oncology

approaches for obtaining these data. However, we seek
138
comment about a potential method to estimate the drug add-on
amount for drugs furnished in hospital-based facilities, and
we seek comment about alternative estimation methodologies,
data, or both.
One estimation approach could be an approach where the
pricing spread for drugs other than EPO furnished in
hospital based facilities would be assumed to be the same as
for those drugs in independent facilities. This aggregate
approach would assume that the add-on amount for drugs other
than EPO furnished in hospital-based facilities results in
the same relative amount of drugs furnished as for those
drugs in independent facilities. Using aggregate ratios,
the drug add-on amounts calculated for drugs other than EPO
furnished in independent facilities might be extrapolated
for drugs other than EPO furnished in hospital-based
facilities.
Use of this approach could allow calculation of a
reasonable estimate of aggregate drug add-on amount for
drugs other than EPO furnished in hospital-based facilities
until the time that data becomes available to more
accurately calculate the drug add-on adjustment. This
approach would allow payment of all drugs furnished in
hospital-based facilities under the ASP +6 percent payment
methodology, achieve consistent payments for ESRD separately